Avesani G. - AI Profile | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 17 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

PD34-10 FIRST RESULTS OF NURE-COMBO: a PHASE 2 STUDY OF NEOADJUVANT NIVOLUMAB (NIVO) AND NAB-PACLITAXEL (ABX) FOLLOWED BY POSTSURGICAL ADJUVANT NIVO IN PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC)

Andrea Necchi,Chiara Mercinelli,Giuseppe Basile,Daniele Raggi,Antonio Cigliola,Valentina Tateo,Damiano Patanè,Emanuele Crupi,Maurizio Colecchia,Marco Moschini,Giulio Avesani,Giorgio Brembilla,Francesco De Cobelli, Alberto Briganti,Jeffrey Ross,Francesco Montorsi

Journal of Urology（2024）

Cited0Views0Bibtex

Cancer Control Rates in Adequate Versus Inadequate Treatment with Adjuvant Immunotherapy Instillations with BCG

EUROPEAN UROLOGY (2024): S1183-S1184

Cited0Views0Bibtex

Pd02-06 comprehensive genomic profiling (cgp) of clinical t2-4n0m0 muscle-invasive bladder cancer (mibc) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (rc)

Andrea Necchi,Chiara Mercinelli,Daniele Raggi,Valentina Tateo,Antonio Cigliola,Damiano Patanè,Emanuele Crupi,Maurizio Colecchia,Marco Moschini,Giulio Avesani, Alberto Briganti,Francesco Montorsi,Dean Pavlick,Jeffrey Ross

Journal of Urologyno. 5S (2024)

Cited0Views0Bibtex

Comprehensive Genomic Profiling (CGP) of Clinical T2-4N0M0 Muscle-Invasive Bladder Cancer (MIBC) Treated with Neoadjuvant Pembrolizumab or Cisplatin-Based Chemotherapy Before Radical Cystectomy (RC)

C. Mercinelli,D. Raggi,A. Cigliola,V. Tateo,D. A. Patane,E. Crupi,M. Colecchia,M. Moschini, C. Re,G. Avesani,A. Briganti,F. Montorsi,J. S. Ross,R. Graf, D. C. Pavllick,A. Necchi

EUROPEAN UROLOGY (2024): S1914-S1914

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn